CDX-622
Inflammatory Diseases
Phase 1Active
Key Facts
About Celldex Therapeutics
Celldex Therapeutics is a disciplined, R&D-focused biotech with a 40-year legacy, strategically pivoted to become a leader in developing targeted antibody therapeutics for immunology and oncology. Its most advanced asset, barzolvolimab, a mast cell-depleting KIT inhibitor, has demonstrated compelling late-stage data in chronic urticaria and is advancing in multiple inflammatory indications, positioning the company for near-term commercialization. Celldex's strategy leverages proprietary antibody platforms and in-house capabilities to build a diversified pipeline aimed at addressing root causes of disease beyond symptomatic management.
View full company profileTherapeutic Areas
Other Inflammatory Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Amilo-5MER | Galmed Pharmaceuticals | Preclinical |
| Biosimilar to Simponi® (golimumab) | Teva | Under Regulatory Review |
| Fbxo3 Inhibitor Program | Koutif Therapeutics | Pre-clinical |
| SRB1 | SunRock Biopharma | Discovery |
| Follow-on Compounds | Abivax | Research |
| Avdoralimab (IPH5401) | Innate Pharma | Phase 2 |
| Izicopan (IFX-4) | InflaRx | Preclinical |
| IFX002 | InflaRx | Preclinical |